Inclusion Criteria:  At least 18 years of age Is a cancer patient enrolled in the Cancer Patient Immune Response to COVID-19 Vaccine study (a basic science study) MCC 21138 or who has completed the two mRNA-1273 vaccine series prior to March 31, 2021. Understands, agrees and is able to comply with the study procedures and provides written informed consent. Has no known or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reactions to the vaccine or its excipients. Has not received more or less than 2 doses of mRNA-1273 vaccine  Exclusion Criteria:  Participants who will not return for the third vaccine dose